Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 341


Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.

Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM.

Breast Cancer Res Treat. 2011 Sep;129(2):451-8. doi: 10.1007/s10549-011-1645-5. Epub 2011 Jun 28.


Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.

Munzone E, Botteri E, Sandri MT, Esposito A, Adamoli L, Zorzino L, Sciandivasci A, Cassatella MC, Rotmensz N, Aurilio G, Curigliano G, Goldhirsch A, Nolè F.

Clin Breast Cancer. 2012 Oct;12(5):340-6. doi: 10.1016/j.clbc.2012.07.001.


Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.

Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Tumori. 2010 Jan-Feb;96(1):103-10.


Age related influence of triple receptor status on metastatic breast cancer post relapse survival.

Todorovic-Rakovic N, Neskovic-Konstantinovic Z.

J BUON. 2013 Oct-Dec;18(4):851-8.


The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.

Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K, Marmé F, Sohn C, Trumpp A, Rack B, Aktas B, Solomayer EF, Müller V, Janni W, Schneeweiss A, Fehm TN.

Breast Cancer Res Treat. 2013 Jan;137(2):503-10. doi: 10.1007/s10549-012-2382-0. Epub 2012 Dec 28.


HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.

Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Löhberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K.

Breast Cancer Res Treat. 2010 Nov;124(2):403-12. doi: 10.1007/s10549-010-1163-x. Epub 2010 Sep 22.


Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.

Cortesi L, De Matteis E, Cirilli C, Marcheselli L, Proietto M, Federico M.

Tumori. 2012 Nov;98(6):743-50. doi: 10.1700/1217.13498.


Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.

Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M.

Ann Oncol. 2012 May;23(5):1144-50. doi: 10.1093/annonc/mdr434. Epub 2011 Sep 28.


Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.

Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D.

J Clin Oncol. 2007 Nov 20;25(33):5194-202. Epub 2007 Oct 22.


Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study.

Rink M, Chun FK, Dahlem R, Soave A, Minner S, Hansen J, Stoupiec M, Coith C, Kluth LA, Ahyai SA, Friedrich MG, Shariat SF, Fisch M, Pantel K, Riethdorf S.

Eur Urol. 2012 Apr;61(4):810-7. doi: 10.1016/j.eururo.2012.01.017. Epub 2012 Jan 20.


Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy.

Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Oncol Rep. 2010 May;23(5):1213-20.


High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.

Pierga JY, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Diéras V, Rolland E, Mignot L, Mathiot C, Bidard FC.

Ann Oncol. 2012 Mar;23(3):618-24. doi: 10.1093/annonc/mdr263. Epub 2011 Jun 3.


HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.

Wülfing P, Borchard J, Buerger H, Heidl S, Zänker KS, Kiesel L, Brandt B.

Clin Cancer Res. 2006 Mar 15;12(6):1715-20.


Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer.

De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M.

Clin Breast Cancer. 2012 Aug;12(4):264-9. doi: 10.1016/j.clbc.2012.04.004. Epub 2012 May 15.


Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.

Somlo G, Lau SK, Frankel P, Hsieh HB, Liu X, Yang L, Krivacic R, Bruce RH.

Breast Cancer Res Treat. 2011 Jul;128(1):155-63. doi: 10.1007/s10549-011-1508-0. Epub 2011 Apr 16.


Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes.

Peeters DJ, van Dam PJ, Van den Eynden GG, Rutten A, Wuyts H, Pouillon L, Peeters M, Pauwels P, Van Laere SJ, van Dam PA, Vermeulen PB, Dirix LY.

Br J Cancer. 2014 Jan 21;110(2):375-83. doi: 10.1038/bjc.2013.743. Epub 2013 Dec 24.


Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.

Van Belle V, Van Calster B, Brouckaert O, Vanden Bempt I, Pintens S, Harvey V, Murray P, Naume B, Wiedswang G, Paridaens R, Moerman P, Amant F, Leunen K, Smeets A, Drijkoningen M, Wildiers H, Christiaens MR, Vergote I, Van Huffel S, Neven P.

J Clin Oncol. 2010 Sep 20;28(27):4129-34. doi: 10.1200/JCO.2009.26.4200. Epub 2010 Aug 16.


Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?

Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H, Cristofanilli M.

Cancer. 2008 Nov 1;113(9):2422-30. doi: 10.1002/cncr.23852.


Breast cancer subtypes and survival in patients with brain metastases.

Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, Ro J.

Breast Cancer Res. 2008;10(1):R20. doi: 10.1186/bcr1870. Epub 2008 Feb 28.


Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.

Bauer K, Parise C, Caggiano V.

BMC Cancer. 2010 May 21;10:228. doi: 10.1186/1471-2407-10-228.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk